|
|
|
|
LEADER |
09151nma a2202797 u 4500 |
001 |
EB001982085 |
003 |
EBX01000000000000001144987 |
005 |
00000000000000.0 |
007 |
cr||||||||||||||||||||| |
008 |
210512 ||| eng |
020 |
|
|
|a books978-3-03928-115-2
|
020 |
|
|
|a 9783039281152
|
020 |
|
|
|a 9783039281145
|
100 |
1 |
|
|a Gozzelino, Raffaella
|
245 |
0 |
0 |
|a Iron as Therapeutic Targets in Human Diseases Volume 2
|h Elektronische Ressource
|
260 |
|
|
|b MDPI - Multidisciplinary Digital Publishing Institute
|c 2020
|
300 |
|
|
|a 1 electronic resource (440 p.)
|
653 |
|
|
|a Africa
|
653 |
|
|
|a reducibility
|
653 |
|
|
|a cystic fibrosis
|
653 |
|
|
|a T lymphocytes
|
653 |
|
|
|a macrophage
|
653 |
|
|
|a Interleukin-6
|
653 |
|
|
|a ferroportin
|
653 |
|
|
|a cognition
|
653 |
|
|
|a hypoxia
|
653 |
|
|
|a efficacy
|
653 |
|
|
|a lung infection
|
653 |
|
|
|a iron overload
|
653 |
|
|
|a Iron chelators
|
653 |
|
|
|a non-transferrin-bound iron (NTBI)
|
653 |
|
|
|a pig
|
653 |
|
|
|a haem
|
653 |
|
|
|a electron transfer
|
653 |
|
|
|a vascular calcification
|
653 |
|
|
|a central nurse macrophage
|
653 |
|
|
|a Anemia
|
653 |
|
|
|a Hfe
|
653 |
|
|
|a Fe2+-chelating activity
|
653 |
|
|
|a protein binding
|
653 |
|
|
|a COPD
|
653 |
|
|
|a osteoclast
|
653 |
|
|
|a gut microbiota
|
653 |
|
|
|a acute lung injury
|
653 |
|
|
|a mitochondria
|
653 |
|
|
|a iron chelation therapy
|
653 |
|
|
|a NCOA4
|
653 |
|
|
|a ferroptosis
|
653 |
|
|
|a malaria
|
653 |
|
|
|a brain
|
653 |
|
|
|a non-haem iron
|
653 |
|
|
|a inflammatory bowel disease (IBD)
|
653 |
|
|
|a low and middle income countries
|
653 |
|
|
|a senescence
|
653 |
|
|
|a serum biomarker
|
653 |
|
|
|a neurodegeneration
|
653 |
|
|
|a binding ability
|
653 |
|
|
|a osteoblast
|
653 |
|
|
|a therapy
|
653 |
|
|
|a hemorrhage
|
653 |
|
|
|a erythrophagocytosis
|
653 |
|
|
|a antitumor compound
|
653 |
|
|
|a chronic heart failure
|
653 |
|
|
|a erythropoiesis
|
653 |
|
|
|a red pulp macrophage
|
653 |
|
|
|a neuroinflammation
|
653 |
|
|
|a M cells
|
653 |
|
|
|a natural history
|
653 |
|
|
|a Anemia of chronic disease
|
653 |
|
|
|a developmental
|
653 |
|
|
|a RRM2
|
653 |
|
|
|a oxygen sensing
|
653 |
|
|
|a nanotechnology
|
653 |
|
|
|a Iron-sulfur
|
653 |
|
|
|a colorectal cancer
|
653 |
|
|
|a 3-hydroxy-4-pyridinone
|
653 |
|
|
|a chronic kidney disease
|
653 |
|
|
|a Biology, life sciences / bicssc
|
653 |
|
|
|a fluorophore
|
653 |
|
|
|a mycobacteria
|
653 |
|
|
|a pulmonary arterial hypertension
|
653 |
|
|
|a cancer
|
653 |
|
|
|a lung diseases
|
653 |
|
|
|a iron supplementation
|
653 |
|
|
|a NaFeEDTA
|
653 |
|
|
|a cardiovascular disease
|
653 |
|
|
|a iron chelators
|
653 |
|
|
|a SLC40A1
|
653 |
|
|
|a biomarker
|
653 |
|
|
|a iron homeostasis
|
653 |
|
|
|a lipid
|
653 |
|
|
|a neurodegeneration with brain iron accumulation
|
653 |
|
|
|a neuroimmune responses
|
653 |
|
|
|a non-HFE
|
653 |
|
|
|a phlebotomy
|
653 |
|
|
|a iron-carbohydrate complex
|
653 |
|
|
|a social behavior
|
653 |
|
|
|a peritoneal dialysis
|
653 |
|
|
|a iron metabolism
|
653 |
|
|
|a cardiomyocyte
|
653 |
|
|
|a FeSO4
|
653 |
|
|
|a anti-hepcidin therapy
|
653 |
|
|
|a flavin nucleotide
|
653 |
|
|
|a prevention
|
653 |
|
|
|a cinnamic acid derivatives
|
653 |
|
|
|a TNF
|
653 |
|
|
|a haptoglobin
|
653 |
|
|
|a iron deficiency anemia
|
653 |
|
|
|a hemolysis
|
653 |
|
|
|a hereditary hyperferritinemia
|
653 |
|
|
|a bioengineering
|
653 |
|
|
|a metabolism
|
653 |
|
|
|a Oxidative stress
|
653 |
|
|
|a age-related macular degeneration (AMD)
|
653 |
|
|
|a drug delivery
|
653 |
|
|
|a Tfr2
|
653 |
|
|
|a adverse event profile
|
653 |
|
|
|a anaemia
|
653 |
|
|
|a liver
|
653 |
|
|
|a innate immunity
|
653 |
|
|
|a osteoporosis
|
653 |
|
|
|a microbiome
|
653 |
|
|
|a MHC
|
653 |
|
|
|a intestinal inflammation
|
653 |
|
|
|a nutrient iron
|
653 |
|
|
|a anemia of inflammation
|
653 |
|
|
|a retina
|
653 |
|
|
|a hemochromatosis
|
653 |
|
|
|a immunity
|
653 |
|
|
|a bacteria
|
653 |
|
|
|a iron absorption
|
653 |
|
|
|a iron chelation
|
653 |
|
|
|a multifunctional iron chelators
|
653 |
|
|
|a pituitary
|
653 |
|
|
|a inflammation
|
653 |
|
|
|a Friedreich Ataxia
|
653 |
|
|
|a mucosal immunity
|
653 |
|
|
|a n/a
|
653 |
|
|
|a soybean seed ferritin
|
653 |
|
|
|a SNC
|
653 |
|
|
|a neonatal
|
653 |
|
|
|a infants
|
653 |
|
|
|a hereditary hypoferritinemia
|
653 |
|
|
|a hemopexin
|
653 |
|
|
|a cytokines
|
653 |
|
|
|a oral iron therapy
|
653 |
|
|
|a pulmonary arterial smooth muscle cells
|
653 |
|
|
|a cataracts syndrome
|
653 |
|
|
|a anemia
|
653 |
|
|
|a iron regulatory proteins
|
653 |
|
|
|a non transferrin bound iron
|
653 |
|
|
|a Mek/Erk
|
653 |
|
|
|a heme homeostasis
|
653 |
|
|
|a heme oxygenase
|
653 |
|
|
|a pharmaceutical targets
|
653 |
|
|
|a heme
|
653 |
|
|
|a infection
|
653 |
|
|
|a erythroblastic islands
|
653 |
|
|
|a children
|
653 |
|
|
|a brain development
|
653 |
|
|
|a SCFA
|
653 |
|
|
|a Bmp/Smad
|
653 |
|
|
|a CD8+ T cells
|
653 |
|
|
|a iron dextran
|
653 |
|
|
|a rheumatoid arthritis
|
653 |
|
|
|a neurodegenerative diseases
|
653 |
|
|
|a NBIA
|
653 |
|
|
|a iron mobilization
|
653 |
|
|
|a venesections
|
653 |
|
|
|a iron deficiency
|
653 |
|
|
|a tolerability
|
653 |
|
|
|a antibacterial activity
|
653 |
|
|
|a chaotropes
|
653 |
|
|
|a chelation
|
653 |
|
|
|a Indonesia
|
653 |
|
|
|a macrophages
|
653 |
|
|
|a kinetics
|
653 |
|
|
|a nanocage
|
653 |
|
|
|a lung
|
653 |
|
|
|a trauma
|
653 |
|
|
|a obesity
|
653 |
|
|
|a neonatal period
|
653 |
|
|
|a supplementation
|
653 |
|
|
|a bone homeostasis
|
653 |
|
|
|a growth
|
653 |
|
|
|a treatment
|
653 |
|
|
|a genetic hemochromatosis
|
653 |
|
|
|a Kupffer cell
|
653 |
|
|
|a kidney
|
653 |
|
|
|a iron release
|
653 |
|
|
|a labile iron
|
653 |
|
|
|a didox
|
653 |
|
|
|a iron
|
653 |
|
|
|a IV iron therapy
|
653 |
|
|
|a Sucrosomial® iron
|
653 |
|
|
|a neurophysiology
|
653 |
|
|
|a fluorescent iron chelator
|
653 |
|
|
|a neurodegenerative disease
|
653 |
|
|
|a iron processing
|
653 |
|
|
|a iron transporters
|
653 |
|
|
|a chelators
|
653 |
|
|
|a intravenous iron
|
653 |
|
|
|a oxidative stress
|
653 |
|
|
|a transferrin receptor
|
653 |
|
|
|a ferritinophagy
|
653 |
|
|
|a HFE
|
653 |
|
|
|a Alzheimer's disease
|
653 |
|
|
|a iron delivery
|
653 |
|
|
|a patient blood management
|
653 |
|
|
|a acute kidney injury
|
653 |
|
|
|a histidine
|
653 |
|
|
|a membrane interactions
|
653 |
|
|
|a ferritin
|
653 |
|
|
|a rhodamine
|
653 |
|
|
|a flavonoids
|
653 |
|
|
|a oral iron salts
|
653 |
|
|
|a developing countries
|
653 |
|
|
|a bioavailability
|
653 |
|
|
|a hepcidin
|
700 |
1 |
|
|a Poli, Maura
|
700 |
1 |
|
|a Arosio, Paolo
|
041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
989 |
|
|
|b DOAB
|a Directory of Open Access Books
|
500 |
|
|
|a Creative Commons (cc), https://creativecommons.org/licenses/by-nc-nd/4.0/
|
028 |
5 |
0 |
|a 10.3390/books978-3-03928-115-2
|
856 |
4 |
2 |
|u https://directory.doabooks.org/handle/20.500.12854/50680
|z DOAB: description of the publication
|
856 |
4 |
0 |
|u https://www.mdpi.com/books/pdfview/book/2017
|7 0
|x Verlag
|3 Volltext
|
082 |
0 |
|
|a 900
|
082 |
0 |
|
|a 612
|
082 |
0 |
|
|a 610
|
082 |
0 |
|
|a 333
|
082 |
0 |
|
|a 380
|
082 |
0 |
|
|a 700
|
082 |
0 |
|
|a 600
|
082 |
0 |
|
|a 620
|
520 |
|
|
|a Iron is an essential element for almost all organisms, a cofactor playing a crucial role in a number of vital functions, including oxygen transport, DNA synthesis, and respiration. However, its ability to exchange electrons renders excess iron potentially toxic, since it is capable of catalyzing the formation of highly poisonous free radicals. As a consequence, iron homeostasis is tightly controlled by sophisticated mechanisms that have been partially elucidated. Because of its biological importance, numerous disorders have been recently linked to the deregulation of iron homeostasis, which include not only the typical disorders of iron overload and deficiency but also cancer and neurodegenerative diseases. This leads iron metabolism to become an interesting therapeutic target for novel pharmacological treatments against these diseases. Several therapies are currently under development for hematological disorders, while other are being considered for different pathologies. The therapeutic targeting under study includes the hepcidin/ferroportin axis for the regulation of systemic iron homeostasis, complex cytosolic machineries for the regulation of the intracellular iron status and its association with oxidative damage, and reagents exploiting proteins of iron metabolism such as ferritin and transferrin receptor. A promising potential target is a recently described form of programmed cell death named ferroptosis, in which the role of iron is essential but not completely clarified. This Special Issue has the aim to summarize the state-of-the-art, and the latest findings published in the iron field, as well as to elucidate future directions.
|